Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine Liposomes vs Bupivacaine for Analgesia After TKA
NCT06653621Phase 4Not yet recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of bupivacaine in postoperative pain (4 arms), sponsored by Huazhong University of Science and Technology. Primary endpoint: Opioid consumption 72 hours after surgery. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06653621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653621.